The APS Report: The Flaws Remain

I would like to respond to the adverse comments made in these pages by Robert L. Park of the American Physical Society (APS) concerning my testimony before a committee of congressmen in May 1987 (September 7, 1987, P. 13). I believe the merits of the Strategic Defense Initiative program inevitably will emerge as its development proceeds—if it receives adequate funding as well as the technical and administrative support it deserves. The SDI organization (SDIO) does have a need, as do

Written byFrederick Seitz
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

I would like to respond to the adverse comments made in these pages by Robert L. Park of the American Physical Society (APS) concerning my testimony before a committee of congressmen in May 1987 (September 7, 1987, P. 13).

I believe the merits of the Strategic Defense Initiative program inevitably will emerge as its development proceeds—if it receives adequate funding as well as the technical and administrative support it deserves.

The SDI organization (SDIO) does have a need, as does any similar enterprise, for an effective not-for-profit, federally funded research center—similar to the Lincoln Laboratory or the Aerospace Corp.—to give it wide access to various types of technological support. Along with others who have been deeply concerned about the security of the Free World and the Soviet Union’s aggressive buildup of space defense systems and offensive strategic weapons, I have urged Congress to authorize the creation of such a research ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies